Drawing for HUMAN PROTEINS FOR HUMAN BEINGS

USPTO serial 78143386

HUMAN PROTEINS FOR HUMAN BEINGS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with HUMAN PROTEINS FOR HUMAN BEINGS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mary S. Consalvi

MARY S CONSALVI MARY S CONSALVI195 ALBANY STCAMBRIDGE, MA 02139UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals and biologics for use in the treatment of genetic disorders, cancer, hematologic disorders, endocrine disorders, reproductive dysfunction, short stature, diabetes, metabolic disorders, disorders of the central nervous system, gastrointestinal disorders, cardiovascular disorders, autoimmune disorders and other disorders of the immune system, infectious diseases and enzyme deficiency diseases; genetically altered cells and cell lines for use in the production of human therapeutic proteins, for medical diagnostic use, for use in the treatment of a variety of diseases and disorders and for implantation into human patientsACTIVE—
042Product research and development services for others in the field of pharmaceuticals and biologics; consulting services in the field of pharmaceutical and biologic production methods, and in the field of clinical protocols for pharmaceuticals and biologics; scientific research services; health care services; diagnostic and genetic medical testing services; medical patient monitoring services; providing information to others about pharmaceuticals, biologics and health care; intellectual property licensing services in the field of pharmaceuticals and biologicsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jan 7, 2004ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 9, 2003GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 8, 2003ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jan 21, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 16, 2003DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance